Vident Advisory LLC Sells 3,382 Shares of Bristol-Myers Squibb (NYSE:BMY)

Vident Advisory LLC cut its holdings in shares of Bristol-Myers Squibb (NYSE:BMY) by 4.3% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 74,513 shares of the biopharmaceutical company’s stock after selling 3,382 shares during the period. Vident Advisory LLC’s holdings in Bristol-Myers Squibb were worth $4,215,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Westwood Holdings Group Inc. boosted its stake in Bristol-Myers Squibb by 397.2% in the fourth quarter. Westwood Holdings Group Inc. now owns 25,191 shares of the biopharmaceutical company’s stock valued at $1,425,000 after acquiring an additional 20,124 shares in the last quarter. St. Clair Advisors LLC acquired a new stake in Bristol-Myers Squibb in the fourth quarter valued at approximately $339,000. Triglav Skladi D.O.O. acquired a new stake in Bristol-Myers Squibb in the fourth quarter valued at approximately $1,635,000. Texas Bank & Trust Co acquired a new stake in Bristol-Myers Squibb in the fourth quarter valued at approximately $747,000. Finally, TrinityPoint Wealth LLC boosted its stake in Bristol-Myers Squibb by 21.3% in the fourth quarter. TrinityPoint Wealth LLC now owns 7,948 shares of the biopharmaceutical company’s stock valued at $450,000 after acquiring an additional 1,398 shares in the last quarter. 76.41% of the stock is currently owned by institutional investors.

Insider Activity

In related news, EVP Samit Hirawat bought 4,250 shares of the company’s stock in a transaction dated Friday, April 25th. The shares were acquired at an average price of $47.58 per share, for a total transaction of $202,215.00. Following the completion of the transaction, the executive vice president now directly owns 83,513 shares in the company, valued at $3,973,548.54. This trade represents a 5.36% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Company insiders own 0.07% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have weighed in on BMY. UBS Group lowered their target price on shares of Bristol-Myers Squibb from $60.00 to $54.00 and set a “neutral” rating for the company in a research note on Friday, April 11th. William Blair reaffirmed a “market perform” rating on shares of Bristol-Myers Squibb in a report on Friday, April 25th. Argus raised shares of Bristol-Myers Squibb to a “hold” rating in a report on Friday, April 25th. Citigroup raised their price target on shares of Bristol-Myers Squibb from $60.00 to $65.00 and gave the stock a “neutral” rating in a report on Tuesday, January 28th. Finally, Piper Sandler began coverage on shares of Bristol-Myers Squibb in a report on Tuesday, April 22nd. They issued an “overweight” rating and a $65.00 price target for the company. Two analysts have rated the stock with a sell rating, thirteen have assigned a hold rating, five have issued a buy rating and three have assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $58.00.

Bristol-Myers Squibb Stock Up 1.3%

BMY opened at $47.84 on Wednesday. Bristol-Myers Squibb has a fifty-two week low of $39.35 and a fifty-two week high of $63.33. The company has a debt-to-equity ratio of 2.90, a quick ratio of 1.15 and a current ratio of 1.25. The company has a fifty day moving average of $52.55 and a two-hundred day moving average of $55.89. The stock has a market capitalization of $97.36 billion, a price-to-earnings ratio of -10.82, a PEG ratio of 2.07 and a beta of 0.39.

Bristol-Myers Squibb (NYSE:BMY) last released its quarterly earnings data on Thursday, April 24th. The biopharmaceutical company reported $1.80 earnings per share for the quarter, beating analysts’ consensus estimates of $1.50 by $0.30. Bristol-Myers Squibb had a negative net margin of 18.53% and a positive return on equity of 13.93%. The company had revenue of $11.20 billion during the quarter, compared to analysts’ expectations of $10.77 billion. During the same quarter in the previous year, the company earned ($4.40) earnings per share. The firm’s revenue for the quarter was down 5.6% on a year-over-year basis. On average, research analysts expect that Bristol-Myers Squibb will post 6.74 earnings per share for the current year.

Bristol-Myers Squibb Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Thursday, May 1st. Stockholders of record on Friday, April 4th were given a $0.62 dividend. The ex-dividend date was Friday, April 4th. This represents a $2.48 annualized dividend and a dividend yield of 5.18%. Bristol-Myers Squibb’s dividend payout ratio (DPR) is 92.88%.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.